Drug Trial Radar · NCT01397461
Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo
Last checked: Nov 19, 2026Latest source record: Jul 1, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
465
Actual
Start
Mar 2012
Primary completion
Dec 2012
Study completion Dec 2012
Sponsor
- Lead sponsor
- Ferrer Internacional S.A.Industry
- Sponsor type
- Industry
- First posted
- Jul 19, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is multicenter, randomised, placebo controlled, parallel, blinded (double-blind for ozenoxacin versus placebo comparison and investigator blinded for retapamulin versus placebo comparison), superiority clinical study comparing ozenoxacin cream versus placebo and retapamulin ointment vs placebo, in patients with a clinical diagnosis of non-bullous or bullous impetigo.
Conditions
- Impetigo
Interventions
ozenoxacin placeboDrug
cream
retapamulin 1% ointmentDrug
ointment
ozenoxacin 1% creamDrug
1% cream
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical SuccessTime frame: 2 weeks
Locations
19 sites in 2 countries. Site status is shown where the registry gives one.
Georg Popp
Augsburg, Germany
Klaus Chelius
Cologne, Germany
Roland Aschoff
Dresden, Germany
Diamant Thaci
Frankfurt am Main, Germany
Stephan Schilling
Mahlow, Germany
Ismail Mitha
Benoni, South Africa
Johan Lombaard
Bloemfontein, South Africa
Jan Fourie
Dundee, South Africa
Dawie Kruger
George, South Africa
Philip Nel
Hatfield, South Africa
Essack Mitha
Johannesburg, South Africa
J Trokis
Kraaifontein, South Africa
Mohammed Tayob
Middelburg, South Africa
Mashra Gani
Port Elizabeth, South Africa
Zelda Punt
Port Elizabeth, South Africa
Molefe Phayane
Pretoria, South Africa
Gail Todd
Rondebosch, South Africa
Yacoob Vahed
Welkom, South Africa
Christo van Dyk
Worcester, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.